ReviewSurgical neurology international2025
Middle meningeal artery embolization for migraine: A review.
Review in Surgical neurology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Migraine and chronic headaches are highly prevalent disorders representing billions in healthcare spending and significantly reduced quality of life. The middle meningeal artery (MMA) is an established target in intracranial pathologies, and MMA embolization may be an innovative and promising therapeutic approach in the management of chronic headaches. Methods: This review of the literature aims to provide an in-depth analysis of the current state of knowledge regarding the effectiveness, safety, and potential implications of surgical targeting of the MMA, with particular emphasis on MMA embolization in the treatment of migraines and chronic headaches. PubMed was systematically queried for studies of MMA Embolization for the treatment of headache. Results: The trigeminovascular system is uniquely implicated in the pathogenesis of migraine headaches. Significant improvement in symptoms has been shown when targeting the neural, chemical, and vascular components of this system. The MMA has demonstrated unique behavior during and after migraines, distinct from that of other intracranial vessels. Reports of MMA perturbance have demonstrated prolonged improvements in migraine-induced pain without major adverse effects. Conclusion: The MMA's unique role in the pathophysiology of migraines renders it a unique target for therapeutic intervention. Early studies revealing clinical migraine benefit after MMA disruption underscore the potential therapeutic value of MMA embolization. MMA embolization has been demonstrated to be safe and feasible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.